ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $84.50, for a total transaction of $105,625.00. Following the completion of the sale, the chief financial officer now directly owns 71,772 shares of the company’s stock, valued at approximately $6,064,734. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Brett Sandercock also recently made the following trade(s):

  • On Monday, October 2nd, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $77.05, for a total transaction of $96,312.50.
  • On Friday, September 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $77.56, for a total transaction of $96,950.00.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million during the quarter, compared to the consensus estimate of $506.08 million. During the same quarter last year, the firm posted $0.62 EPS. The company’s quarterly revenue was up 12.5% on a year-over-year basis.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be given a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.66%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is presently 56.68%.

COPYRIGHT VIOLATION WARNING: “ResMed Inc. (RMD) CFO Sells $105,625.00 in Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/02/resmed-inc-rmd-cfo-sells-105625-00-in-stock.html.

Several research firms recently issued reports on RMD. Jefferies Group LLC reaffirmed a “sell” rating and issued a $56.00 price objective on shares of ResMed in a research note on Thursday, October 12th. Zacks Investment Research raised shares of ResMed from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a research note on Thursday, July 6th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a research note on Friday, September 8th. Citigroup Inc. raised shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 2nd. Finally, BMO Capital Markets lifted their price objective on shares of ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a research note on Friday, October 27th. Four research analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. ResMed presently has a consensus rating of “Hold” and an average target price of $67.57.

Several institutional investors and hedge funds have recently made changes to their positions in RMD. MARSHALL WACE ASIA Ltd acquired a new stake in shares of ResMed during the 1st quarter worth about $269,000. Marshall Wace North America L.P. acquired a new stake in shares of ResMed during the 1st quarter worth about $269,000. Dimensional Fund Advisors LP lifted its stake in shares of ResMed by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 376,787 shares of the medical equipment provider’s stock worth $27,116,000 after buying an additional 12,601 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of ResMed during the 1st quarter worth about $523,000. Finally, Public Employees Retirement System of Ohio lifted its stake in shares of ResMed by 2.8% during the 1st quarter. Public Employees Retirement System of Ohio now owns 62,672 shares of the medical equipment provider’s stock worth $4,511,000 after buying an additional 1,703 shares during the last quarter. 59.66% of the stock is owned by institutional investors.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.